You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Therapeutic for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the treatment of liver fibrosis include changes in diet, life-style and/or medications to allevate the unde ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Anti-Fibrotic Therapy for Scleroderma/SSc

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, blood vessels, GI and kidney. Many patients who suffer from scleroderma/SSc also have a loss of pulmonary function. Scleroderma/SSc affects approximately 400,000 to 900,000 people in th ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Real-time Adherence and Risk Management of Opioid Therapies

    SBC: MedicaSafe Inc            Topic: NIDA

    DESCRIPTION (provided by applicant): Following a highly successful Phase I award, this Phase II SBIR application proposes development of MedicaSafe Opioids - a risk management system for the treatment of chronic pain patients prescribed opioid therapies. The need for this system arises from the dramatic increase in the use of opiod painkillers. Although this form of medication can be highly effect ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical System for Measurement of Oral Crest Height Change in Dental Radiographs

    SBC: Imagination Software Corporation            Topic: NIDCR

    DESCRIPTION (provided by applicant): Twenty-six percent of the population twenty years and over have destructive periodontal disease (gt 4 mm loss of bone height). Alveolar bone height correlates well with subsequent tooth loss. Moreover, it has been foundthat periodontal disease correlates with other diseases, e.g., atherosclerosis and diabetes. Proper diagnosis, treatment, maintenance, and patie ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic lik

    SBC: Caladrius Biosciences            Topic: NIDCR

    DESCRIPTION (provided by applicant): Bone loss due to fractures and disease is a serious medical condition in the US affecting millions of Americans. It is particularly a problem with oral craniofacial disorders were the costs of treating damage exceeds60 billion annually. Furthermore, periodontitis is associated with systemic disorders such as diabetes mellitus, preterm low birth weight, and car ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Antifibrotic Therapy for Chronic Kidney Disease

    SBC: Angion Biomedica Corp.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic strategies oppose the molecular and cellular program of fibrosis that drives renal disease. There ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Gene transfer to treat urinary urgency frequency nocturia and incontinence

    SBC: Ion Channel Innovations, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): This grant application is initiated by Ion Channel Innovations, LLC., (ICI) an early stage biotechnology company that has completed the first, and only, phase I safety trial using plasmid DNA transfer with a non-specific gene MaxiK potassium channel promoter to treat urinary urgency, frequency, nocturia, and incontinence also known as overactive bladder or OAB ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. NOVEL HIGH THROUGHPUT PLATFORM FOR SCREENING CYTOCHROME P450 INDUCTION

    SBC: ORIGINUS, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Many prescribed drugs exhibit drug-drug interactions due to up-regulation or inhibition of specific P450 enzymes. According to a recent guidance from the FDA, CYP1A2, CYP2B6, and CYP3A4 induction should be evaluated inat least an in vitro system. Enzymatic activity in freshly isolated hepatocytes is the Gold Standard for studying P450 induction; however, it ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Compact, cost-effective, and operator-friendly fundus camera for early detection

    SBC: LUMETRICS, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): This SBIR application will revolutionize the methodology for routine examination of the back of the eye by developing an easy-to-use, pocket-sized, inexpensive digital camera for documenting retinal and optic nerve diseases. In order to reduce rates of preventable vision loss, the early diagnosis of treatable eye diseases has become increasingly important, espe ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Photoactivated Antimicrobial Collagen

    SBC: CONVERSION ENERGY ENTERPRISES            Topic: NIGMS

    DESCRIPTION (provided by applicant): The significance of this project is the development of a novel photoactivated collagen dressing with demonstrated bactericidal effects, minimal toxic effects and low susceptibility to mechanisms of microbial resistancein an effort to ultimately expand the armamentarium of antimicrobial agents for the management of wound infections. Approximately 2 million patie ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government